{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T01:47:38Z","timestamp":1782611258562,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2015,9,25]],"date-time":"2015-09-25T00:00:00Z","timestamp":1443139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s40265-015-0475-x","type":"journal-article","created":{"date-parts":[[2015,9,25]],"date-time":"2015-09-25T08:18:12Z","timestamp":1443169092000},"page":"1797-1806","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.1007","volume":"75","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian M.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,25]]},"reference":[{"issue":"9569","key":"475_CR1","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287\u2013301.","journal-title":"Lancet."},{"issue":"1","key":"475_CR2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2015.59","volume":"88","author":"AB Chapman","year":"2015","unstructured":"Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 2015;88(1):17\u201327.","journal-title":"Kidney Int."},{"key":"475_CR3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/1471-2369-15-182","volume":"15","author":"AP McGovern","year":"2014","unstructured":"McGovern AP, Jones S, van Vlymen J, et al. Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study. BMC Nephrol. 2014;15:182.","journal-title":"BMC Nephrol."},{"issue":"6","key":"475_CR4","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/ndt\/gfs551","volume":"28","author":"HP Neumann","year":"2013","unstructured":"Neumann HP, Jilg C, Bacher J, et al. Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany. Nephrol Dial Transplant. 2013;28(6):1472\u201387.","journal-title":"Nephrol Dial Transplant."},{"issue":"Suppl 4","key":"475_CR5","doi-asserted-by":"crossref","first-page":"iv95","DOI":"10.1093\/ndt\/gfu186","volume":"29","author":"E Ars","year":"2014","unstructured":"Ars E, Bernis C, Fraga G, et al. Spanish guidelines for the management of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2014;29(Suppl 4):iv95\u2013105.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"475_CR6","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","volume":"24","author":"E Cornec-Le Gall","year":"2013","unstructured":"Cornec-Le Gall E, Audrezet MP, Chen JM, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013;24(6):1006\u201313.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"475_CR7","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/14656566.2014.903923","volume":"15","author":"RP Wuthrich","year":"2014","unstructured":"Wuthrich RP, Mei C. Pharmacological management of polycystic kidney disease. Expert Opin Pharmacother. 2014;15(8):1085\u201395.","journal-title":"Expert Opin Pharmacother."},{"key":"475_CR8","unstructured":"European Medicines Agency. Tolvaptan (Samsca): summary of product characteristics. http:\/\/www.ema.europa.eu . Accessed 18 Sep 2015."},{"issue":"5","key":"475_CR9","doi-asserted-by":"crossref","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","volume":"301","author":"GA Reif","year":"2011","unstructured":"Reif GA, Yamaguchi T, Nivens E, et al. Tolvaptan inhibits ERK-dependent cell proliferation, Cl(\u2212) secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol. 2011;301(5):F1005\u201313.","journal-title":"Am J Physiol Renal Physiol."},{"issue":"8","key":"475_CR10","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","volume":"26","author":"E Meijer","year":"2011","unstructured":"Meijer E, Gansevoort RT, de Jong PE, et al. Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Nephrol Dial Transplant. 2011;26(8):2445\u201353.","journal-title":"Nephrol Dial Transplant."},{"key":"475_CR11","unstructured":"European Medicines Agency. Tolvaptan (Jinarc): summary of product characteristics. 2015. http:\/\/www.ema.europa.eu . Accessed 18 Sep 2015."},{"issue":"2","key":"475_CR12","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1124\/jpet.114.213256","volume":"349","author":"M Aihara","year":"2014","unstructured":"Aihara M, Fujiki H, Mizuguchi H, et al. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury. J Pharmacol Exp Ther. 2014;349(2):258\u201367.","journal-title":"J Pharmacol Exp Ther."},{"issue":"12","key":"475_CR13","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1177\/0091270007307877","volume":"47","author":"SE Shoaf","year":"2007","unstructured":"Shoaf SE, Wang Z, Bricmont P, et al. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J Clin Pharmacol. 2007;47(12):1498\u2013507.","journal-title":"J Clin Pharmacol."},{"key":"475_CR14","unstructured":"European Medicines Agency. Jinarc assessment report. 2015. http:\/\/www.ema.europa.eu . Accessed 18 Sep 2015."},{"issue":"5","key":"475_CR15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","volume":"57","author":"VE Torres","year":"2011","unstructured":"Torres VE, Meijer E, Bae KT, et al. Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3\u20134 study. Am J Kidney Dis. 2011;57(5):692\u20139.","journal-title":"Am J Kidney Dis."},{"issue":"10","key":"475_CR16","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2215\/CJN.03530411","volume":"6","author":"E Higashihara","year":"2011","unstructured":"Higashihara E, Torres VE, Chapman AB, et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years\u2019 experience. Clin J Am Soc Nephrol. 2011;6(10):2499\u2013507.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"3","key":"475_CR17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ki.2011.119","volume":"80","author":"MV Irazabal","year":"2011","unstructured":"Irazabal MV, Torres VE, Hogan MC, et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2011;80(3):295\u2013301.","journal-title":"Kidney Int."},{"issue":"6","key":"475_CR18","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1053\/j.ajkd.2014.11.010","volume":"65","author":"WE Boertien","year":"2015","unstructured":"Boertien WE, Meijer E, de Jong PE, et al. Short-term effects of tolvaptan in individuals with autosomal dominant polycystic kidney disease at various levels of kidney function. Am J Kidney Dis. 2015;65(6):833\u201341.","journal-title":"Am J Kidney Dis."},{"issue":"6","key":"475_CR19","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/ki.2013.285","volume":"84","author":"WE Boertien","year":"2013","unstructured":"Boertien WE, Meijer E, de Jong PE, et al. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. Kidney Int. 2013;84(6):1278\u201386.","journal-title":"Kidney Int."},{"issue":"2","key":"475_CR20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/FJC.0b013e318074f934","volume":"50","author":"SE Shoaf","year":"2007","unstructured":"Shoaf SE, Bramer SL, Bricmont P, et al. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. J Cardiovasc Pharmacol. 2007;50(2):213\u201322.","journal-title":"J Cardiovasc Pharmacol."},{"issue":"4","key":"475_CR21","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/ki.2013.350","volume":"85","author":"SE Shoaf","year":"2014","unstructured":"Shoaf SE, Bricmont P, Mallikaarjun S. Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function. Kidney Int. 2014;85(4):953\u201361.","journal-title":"Kidney Int."},{"issue":"12","key":"475_CR22","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00228-012-1295-5","volume":"68","author":"SE Shoaf","year":"2012","unstructured":"Shoaf SE, Kim SR, Bricmont P, et al. Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects. Eur J Clin Pharmacol. 2012;68(12):1595\u2013603.","journal-title":"Eur J Clin Pharmacol."},{"issue":"25","key":"475_CR23","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407\u201318.","journal-title":"N Engl J Med."},{"key":"475_CR24","unstructured":"Torres VE, Devuyst O, Chapman AB, et al. Effect of tolvaptan in ADPKD by CKD stage: results from the TEMPO 3:4 trial [abstract plus poster]. In: World Congress of Nephrology; 2015."},{"key":"475_CR25","author":"S Muto","year":"2015","unstructured":"Muto S, Kawano H, Higashihara E, et al. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clin Exp Nephrol. 2015. doi: 10.1007\/s10157-015-1086-2 .","journal-title":"Clin Exp Nephrol."},{"key":"475_CR26","unstructured":"Devuyst O, Chapman AB, Boklage S, et al. Tolerability of aquaretic-related symptoms: results from the TEMPO 3:4 trial [abstract plus poster]. In: World Congress of Nephrology; 2015."},{"key":"475_CR27","author":"PB Watkins","year":"2015","unstructured":"Watkins PB, Lewis JH, Kaplowitz N, et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf. 2015. doi: 10.1007\/s40264-015-0327-3 .","journal-title":"Drug Saf."},{"issue":"8","key":"475_CR28","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1681\/ASN.2006030251","volume":"17","author":"S Nagao","year":"2006","unstructured":"Nagao S, Nishii K, Katsuyama M, et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol. 2006;17(8):2220\u20137.","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"475_CR29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","volume":"19","author":"X Wang","year":"2008","unstructured":"Wang X, Wu Y, Ward CJ, et al. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2008;19(1):102\u20138.","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"475_CR30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","volume":"10","author":"VE Torres","year":"2004","unstructured":"Torres VE, Wang X, Qian Q, et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004;10(4):363\u20134.","journal-title":"Nat Med."},{"issue":"9981","key":"475_CR31","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","volume":"385","author":"AC Ong","year":"2015","unstructured":"Ong AC, Devuyst O, Knebelmann B, et al. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet. 2015;385(9981):1993\u20132002.","journal-title":"Lancet."},{"key":"475_CR32","author":"A Alam","year":"2015","unstructured":"Alam A, Dahl NK, Lipschutz JH, et al. Total kidney volume in autosomal dominant polycystic kidney disease: a biomarker of disease progression and therapeutic efficacy. Am J Kidney Dis. 2015. doi: 10.1053\/j.ajkd.2015.01.030 .","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"475_CR33","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ki.2015.71","volume":"88","author":"H Bhutani","year":"2015","unstructured":"Bhutani H, Smith V, Rahbari-Oskoui F, et al. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int. 2015;88(1):146\u201351.","journal-title":"Kidney Int."},{"key":"475_CR34","unstructured":"Otsuka Pharmaceutical Development and Commercialization. Open-label tolvaptan study in subjects with ADPKD (TEMPO 4\/4). 2014. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01214421 . Accessed 18 Sep 2015."},{"key":"475_CR35","unstructured":"Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan-treatment of ADPKD confers persistent EGFR improvement: results from the TEMPO 4:4 extension trial [abstract no. SO016]. In: 51st European Renal Association\u2013European Dialysis and Transplant Association (ERA\u2013EDTA) Congress; 2014."},{"issue":"13","key":"475_CR36","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMc1300762","volume":"368","author":"A Spital","year":"2013","unstructured":"Spital A. Tolvaptan in autosomal dominant polycystic kidney disease. N Engl J Med. 2013;368(13):1257.","journal-title":"N Engl J Med."},{"issue":"4","key":"475_CR37","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.urology.2012.12.002","volume":"81","author":"P Black","year":"2013","unstructured":"Black P, Sutton R. Commentary on: Tolvaptan in patients with autosomal-dominant polycystic kidney disease. Urology. 2013;81(4):705\u20136.","journal-title":"Urology."},{"issue":"13","key":"475_CR38","first-page":"1259","volume":"368","author":"VE Torres","year":"2013","unstructured":"Torres VE, Gansevoort RT, Czerwiec FS. Tolvaptan in autosomal dominant polycystic kidney disease. N Engl J Med. 2013;368(13):1259.","journal-title":"N Engl J Med."},{"key":"475_CR39","unstructured":"National Institute for Health and Care Excellence. Final appraisal determination document\u2014tolvaptan for treating autosomal dominant polycystic kidney disease. 2015. http:\/\/www.nice.org.uk . Accessed 18 Sep 2015."},{"key":"475_CR40","doi-asserted-by":"crossref","unstructured":"Robinson P, McEwan P, Ong ACM, et al. Assessing the long term outcomes of autosomal dominant polycystic kidney disease (ADPKD) using the ADPKD outcomes model: a UK case study [abstract no. FP064 plus poster]. In: 52nd European Renal Association\u2013European Dialysis and Transplant Association (ERA\u2013EDTA) Congress. 2015.","DOI":"10.1093\/ndt\/gfv167.20"},{"key":"475_CR41","doi-asserted-by":"crossref","unstructured":"O\u2019Reilly K, McEwan P, Bennett Wilton H, et al. Exploring the impact of tolvaptan on the long term rate of renal function decline using the ADPKD outcomes model [abstract no. FP055 plus poster]. In: 52nd European Renal Association\u2013European Dialysis and Transplant Association (ERA\u2013EDTA) Congress. 2015.","DOI":"10.1093\/ndt\/gfv167.11"},{"issue":"2","key":"475_CR42","first-page":"e27","volume":"7","author":"CM Blanchette","year":"2015","unstructured":"Blanchette CM, Matter S, Chawla A, et al. Burden of autosomal dominant polycystic kidney disease: systemic literature review. Am J Pharm Benefits. 2015;7(2):e27\u201336.","journal-title":"Am J Pharm Benefits."},{"key":"475_CR43","unstructured":"Otsuka Pharmaceutical Development and Commercialization. Efficacy and safety of tolvaptan in subjects with chronic kidney disease between late stage 2 to early stage 4 due to autosomal dominant polycystic kidney disease. 2014. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02160145 . Accessed 18 Sep 2015."},{"key":"475_CR44","unstructured":"Otsuka Pharmaceutical Development and Commercialization. Open-label trial to evaluate the long term safety of titrated immediate-release tolvaptan in subjects with autosomal dominant polycystic kidney disease. 2014. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02251275 . Accessed 18 Sep 2015."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0475-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0475-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0475-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T07:22:32Z","timestamp":1653204152000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0475-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,25]]},"references-count":44,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["475"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0475-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,25]]}}}